Skip to main content

Advertisement

SpringerLink
Log in

Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background

Although nivolumab has shown clinical benefits for relapsed malignant mesothelioma, its cost-effectiveness requires further investigation.

Aim

This study aimed to evaluate the cost-effectiveness of nivolumab compared to placebo for relapsed malignant mesotheliomas from the perspective of the Chinese healthcare system.

Method

A three-state Markov model was developed based on data from the phase 3 randomized CONFIRM clinical trial. The drug cost and utility values for the health state were obtained from the relevant literature. The measured outcomes included quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER). Probabilistic and one-way sensitivity analyses (OWSA) were performed to assess the uncertainty of the model.

Results

Patients receiving nivolumab gained more health benefits (0.65 QALYs vs. 0.43 QALYs). The cost was higher ($25,806.08 vs. $9,310.74) than for patients in the placebo group, resulting in an ICER of $75,805.11/QALY, which was above the willingness-to-pay (WTP) threshold of three times per capita GDP ($35,864.61) in China. The result of OWSA indicated that the cost of nivolumab, the utility of the disease progression, and the discount rate were the most significant factors. Probabilistic sensitivity analysis suggested that the probability that nivolumab was not cost-effective as was 100.00% above the specified WTP threshold.

Conclusion

From the perspective of the Chinese healthcare system, nivolumab was not as cost-effective as placebo for relapsed malignant mesothelioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Pan D, Wang M, Liu W, et al. Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly. BMC Gastroenterol. 2022;22(1):292.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Scherpereel A, Opitz I, Berghmans T, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1.

    Article  Google Scholar 

  3. Shavelle R, Vavra-Musser K, Lee J, et al. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:2782590.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488–99.

    Article  CAS  PubMed  Google Scholar 

  5. Sahu RK, Ruhi S, Jeppu AK, et al. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front Oncol. 2023;13:1204722.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mansfield AS, Roden AC, Peikert T, et al. B7–H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9(7):1036–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chapel DB, Stewart R, Furtado LV, et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28–8 pharmDx assays. Hum Pathol. 2019;87:11–7.

    Article  CAS  PubMed  Google Scholar 

  8. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485–92.

    Article  CAS  PubMed  Google Scholar 

  9. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569–76.

    Article  PubMed  Google Scholar 

  10. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–53.

    Article  CAS  PubMed  Google Scholar 

  11. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9.

    Article  PubMed  Google Scholar 

  13. Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–51.

    Article  CAS  PubMed  Google Scholar 

  14. Guyot P, Ades AE, Ouwens M, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:13.

    Article  Google Scholar 

  15. Li W, Guo H, Li L, et al. Comprehensive comparison between adjuvant targeted therapy and chemotherapy for EGFR-mutant NSCLC patients: a cost-effectiveness analysis. Front Oncol. 2021;11: 619376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lin YT, Chen Y, Liu TX, et al. Cost-effectiveness analysis of camrelizumab immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma. Cancer Manag Res. 2021;13:8219–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wu B, Li T, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14:984.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Shu Y, Tang Y, Ding Y, et al. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma. Int Immunopharmacol. 2023;122: 110543.

    Article  CAS  PubMed  Google Scholar 

  19. Wen F, Zheng H, Zhang P, et al. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United states. Liver Int. 2021;41(5):1097–104.

    Article  CAS  PubMed  Google Scholar 

  20. Li Y, Liang X, Li H, et al. Nivolumab versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: a cost-effectiveness analysis. Front Pharmacol. 2022;13: 906956.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Scherpereel A, Antonia S, Bautista Y, et al. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022;167:8–16.

    Article  CAS  PubMed  Google Scholar 

  22. Zhan M, Zheng H, Xu T, et al. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. Lung Cancer. 2017;110:1–6.

    Article  PubMed  Google Scholar 

  23. Yang L, Cao X, Li N, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol. 2022;14:17588359221116604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ye ZM, Tang ZQ, Xu Z, et al. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health. 2022;10: 947375.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Xu K, Wu H, Zhou C, et al. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma. Int J Clin Pharm. 2023;45(3):641–9.

    Article  PubMed  Google Scholar 

  26. Zhu Y, Liu K, Qin Q, et al. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis. Front Immunol. 2022;13:1044678.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

No specific funding was received.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China

    Wenwang Lang

  2. Guilin Medical University, Guilin, China

    Jiarong Wei

  3. Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China

    Qinling Jiang, Qi Ai, Xianling Zhao, Liang Xiao & Yulong He

Authors
  1. Wenwang Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiarong Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qinling Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qi Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xianling Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yulong He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenwang Lang.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lang, W., Wei, J., Jiang, Q. et al. Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma. Int J Clin Pharm 46, 158–165 (2024). https://doi.org/10.1007/s11096-023-01662-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-023-01662-1

Keywords

Search

Navigation